A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

What is the purpose of this trial?

A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714).


Participation Guidelines

Ages: 18 years and older

Gender: Both


Bristol-Myers Squibb Company

Dates: 08/31/2017 - 02/01/2018

Last Updated: 09/01/2017

Study HIC#: 2000020641

Get Involved

For more information about this study, contact:
Tenzin Choezom
203-785-3865
t.choezom@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image